Subscribe or Manage Preferences

ESMO 2014 - Immuno-Oncology

Treatments are limited for patients with metastatic urothelial bladder cancer. MPDL3280A is a human monoclonal antibody that is directed against the immune checkpoint receptor programmed death-1 (PD-1) ligand 1 (PD-L1), disrupting PD-L1 binding to its receptors PD-1 and B7.1.
The human monoclonal antibody MPDL3280A is directed against the immune checkpoint receptor programmed death-1 (PD-1) ligand 1(PD-L1), disrupting PD-L1 binding to its receptors PD-1 and B7.1.
Nivolumab is a fully human monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint receptor to restore T-cell antitumor immune responses, and has shown clinical activity in metastatic renal-cell carcinoma (mRCC).
Pembrolizumab is a humanized antibody that exerts dual blockade of the immune checkpoint receptor programmed death-1 (PD-1). It has demonstrated robust antitumor activity and acceptable tolerability in several tumors, including melanoma and lung cancer.
Pembrolizumab is a humanized high-affinity antibody that exerts dual-ligand blockade of the immune checkpoint receptor programmed death-1 (PD-1).
The treatment options for patients with advanced melanoma that have progressed on approved agents is limited. Nivolumab is a fully human monoclonal antibody that is directed toward the immune checkpoint receptor programmed death-1 (PD-1), which has demonstrated durable antimelanoma activity in early clinical trials in pretreated patients with advanced disease.
Nivolumab is a fully human monoclonal antibody that is directed toward the immune checkpoint receptor programmed death-1 (PD-1).
Ipilimumab is an approved immunotherapy that blocks the function of the immune checkpoint modulator CTLA-4 (cytotoxic T-lymphocyte antigen-4) to augment T-cell antitumor immune responses.
Adjuvant chemotherapy is the standard of care for patients with stage II/IIIA non–small-cell lung cancer (NSCLC), as well as for patients with high-risk stage IB NSCLC; however, this is not applicable to all patients, and the 5-year disease-free survival (DFS) has been suboptimal, underscoring the need for novel therapeutic approaches.
Nivolumab is a fully human monoclonal antibody that inhibits the programmed death-1 (PD-1) immune checkpoint receptor to restore T-cell antitumor immune responses.
Page 1 of 2
Results 1 - 10 of 18
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology